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Chk1 and 14-3-3 proteins inhibit atypical E2Fs to
prevent a permanent cell cycle arrest
Ruixue Yuan1, Harmjan R Vos2, Robert M van Es2, Jing Chen1, Boudewijn MT Burgering2,
Bart Westendorp1,* & Alain de Bruin1,3,**
Abstract
The atypical E2Fs, E2F7 and E2F8, act as potent transcriptional
repressors of DNA replication genes providing them with the abil-
ity to induce a permanent S-phase arrest and suppress tumorigen-
esis. Surprisingly in human cancer, transcript levels of atypical
E2Fs are frequently elevated in proliferating cancer cells, suggest-
ing that the tumor suppressor functions of atypical E2Fs might be
inhibited through unknown post-translational mechanisms. Here,
we show that atypical E2Fs can be directly phosphorylated by
checkpoint kinase 1 (Chk1) to prevent a permanent cell cycle
arrest. We found that 14-3-3 protein isoforms interact with both
E2Fs in a Chk1-dependent manner. Strikingly, Chk1 phosphoryla-
tion and 14-3-3-binding did not relocate or degrade atypical E2Fs,
but instead, 14-3-3 is recruited to E2F7/8 target gene promoters to
possibly interfere with transcription. We observed that high levels
of 14-3-3 strongly correlate with upregulated transcription of atyp-
ical E2F target genes in human cancer. Thus, we reveal that Chk1
and 14-3-3 proteins cooperate to inactivate the transcriptional
repressor functions of atypical E2Fs. This mechanism might be of
particular importance to cancer cells, since they are exposed
frequently to DNA-damaging therapeutic reagents.
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Introduction
To cope with intrinsic and extrinsic genotoxic stress, eukaryotes
have developed highly conserved DNA damage signaling pathways.
Intact function of DNA damage signaling is crucial to maintain
genome integrity and is important in preventing the development of
cancer and other diseases (Jackson & Bartek, 2009; Ciccia & Elledge,
2010). In response to DNA lesions, checkpoints can be activated to
halt cell cycle progression until the damage is repaired. Within the
DNA damage signaling network, checkpoint kinase 1 (Chk1) plays a
central role. It is a transducer in arresting the cell cycle, repairing
DNA, and regulating transcription and apoptosis induction (Dai &
Grant, 2010). Chk1 directly phosphorylates multiple substrates to
regulate their activity, stability, or subcellular localization. Well-
characterized substrates of Chk1 include the CDC25 phosphatases,
P53, RAD51, and FANCE, which facilitate cell cycle arrest and repair
in response to DNA damage (Zhang & Hunter, 2014). Also, Chk1
functions to modulate E2F-dependent transcription, because both
E2F3 and E2F6 were identified as Chk1 substrates (Bertoli et al,
2013; Gong et al, 2016).
The E2F transcription factor family is of paramount importance
in coordinating cell cycle progression. Among the known E2F family
members, E2F7 and E2F8 are considered as atypical E2F transcrip-
tion factors, because they do not require binding with retinoblas-
toma protein or heterodimerization with the DNA-binding partner
(DP) proteins to repress target genes. E2F7 and E2F8 levels peak
during S phase, to mediate the downswing of many oscillating target
genes involved in DNA replication, metabolism, and DNA repair.
We previously found that E2F7 and E2F8 are subjected to degrada-
tion via APC/CCdh1 during G1 phase, to allow a time window for
upregulation of E2F target genes by activator E2Fs, and subsequent
S-phase entry (Boekhout et al, 2016). Meanwhile, ectopic expres-
sion of E2F7 and E2F8 is sufficient to stall S-phase progression, indi-
cating that their activity must be carefully regulated to ensure
unperturbed proliferation (Westendorp et al, 2012; Boekhout et al,
2016). Interestingly, there is accumulating evidence suggesting that
atypical E2Fs also play an important role in the DNA damage
response. E2F7 is a transcriptional target of P53 and mediates DNA
damage-induced senescence (Aksoy et al, 2012; Carvajal et al,
2012). Moreover, E2F7 and E2F8 redundantly inhibit DNA synthesis
in primary keratinocytes under etoposide treatment (Thurlings et al,
2016). Furthermore, previous work indicated that E2F7 may relocate
to DNA breaks to regulate homologous recombination and that
E2F7 and E2F8 can suppress E2F1-induced apoptosis after DNA
damage (Zalmas et al, 2008, 2013). We recently demonstrated that
atypical E2Fs can act as tumor suppressors in two murine cancer
models (Kent et al, 2016; Thurlings et al, 2016). These findings
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suggest that balanced activity of E2F7 and E2F8 plays a central role
in cell cycle control during DNA damage and regulation of the
S-phase checkpoint. Nonetheless, the post-translational regulation
mechanisms and precise functions of E2F7 and E2F8 in the DNA
damage response are still unknown.
Here, we demonstrate that Chk1 phosphorylates both E2F7 and
E2F8 in response to DNA damage. Functionally, Chk1 inhibited
E2F7/8 transcriptional repressor activity to prevent severe repres-
sion of E2F target genes. Blockage of this interaction caused a severe
S-phase arrest and apoptosis. Moreover, we found that reduced
repressor activity of the atypical E2Fs was mediated via Chk1-
dependent 14-3-3 binding. In addition, a positive correlation
between E2F7/8 target gene expression and 14-3-3 levels was found
in different types of cancer, including hepatocellular carcinoma.
This suggests that E2F target gene expression could be deregulated
in cancer cells via Chk1/14-3-3-dependent inhibition of atypical
E2Fs.
Results
Chk1 phosphorylates atypical E2Fs
We asked whether atypical E2Fs undergo post-translational modifi-
cations under DNA-damaging conditions. To this end, we carried
out label-free mass spectrometry to detect putative phosphorylation
events on E2F7 and E2F8 in response to treatment with the topo-
isomerase II inhibitor etoposide. Three phosphorylations on human
E2F7 and E2F8 were highly induced in response to DNA damage:
E2F7S410, E2F8S395, and E2F8S412 (Fig EV1A). Interestingly, E2F7S410
and E2F8S395, which locate at a similar position on each E2F, closely
resemble consensus Chk1 target motifs (L/MxRxxS) and are
conserved between human and mouse (Fig 1A and B). Chk1 is a
serine/threonine-specific kinase that phosphorylates protein targets
resulting in the activation of the S-phase cell cycle checkpoint to
allow DNA repair and maintenance of genetic stability (Sanchez
et al, 1997; Syljuasen et al, 2005; Petermann et al, 2010). To test
whether Chk1 is indeed responsible for phosphorylating atypical
E2Fs on the above-described serine residues, we incubated co-
immunoprecipitated Flag-tagged E2F7 or E2F8 with recombinant
active Chk1 and performed mass spectrometry. Again, E2F7S410 and
to a lesser extent E2F8S395 showed increases in phosphorylation
after Chk1 incubation, and a serine at 833 was found in human
E2F7 construct (Fig EV1B). Next, we performed in vitro kinase
assays to confirm that E2F7/8 were indeed substrates of Chk1. In
the kinase assay, E2F7 and E2F8 showed a robust phosphorylation
by active Chk1 (Fig EV1C). Since Ser833 and Ser410 in human E2F7
are conserved in mouse (referred to E2F7S825 and E2F7S411 in
mouse), we decided to focus on mouse constructs in our subsequent
studies. To test what are the primary target amino acids of Chk1
phosphorylation, we performed site-directed mutagenesis to gener-
ate E2F7 and E2F8 constructs in which serines are replaced by alani-
nes (hereafter referred to E2F7S411A and E2F7S825A, E2F8S395A). In
the kinase assay, we found that phosphorylation of both E2F7S411A
and E2F8S395A, but not E2F7S825A, were clearly reduced compared to
their wild-type counterparts, indicating that these serine residues
are indeed the main phosphorylation sites of E2F7 and E2F8
(Fig 1C).
To further confirm these phosphorylation events, we devised
antibodies that recognized the phosphorylation site of E2F7S411 and
E2F8S395. E2F7 and E2F8 are not abundantly expressed, and there-
fore, we had difficulties in detecting endogenous phosphorylated
E2F7 and E2F8. However, we could detect strong protein bands in
cells transfected with exogenous mouse wild-type forms of EGFP-
tagged E2F7 and E2F8, but not the alanine mutants (Fig EV1D). We
then used the phospho-specific antibodies to investigate the
dynamic of the phosphorylation events on exogenous E2F7/8. To
overcome the problem that exogenous E2F7/8 can perturb the cell
cycle (Westendorp et al, 2012), we expressed DNA-binding mutant
versions of E2F7/8 (DBD). As shown in Fig EV1E, phosphorylation
levels of E2F7S411 and E2F8S395 were low before etoposide treatment
but were induced dramatically within 1 h of etoposide treatment,
indicating a rapid response to the activated Chk1 kinase. To exam-
ine whether atypical E2Fs are targets of Chk1 in vivo, we measured
the phosphorylation of E2F7S411 and E2F8Ser395 with siRNA against
Chk1 or with a Chk1 inhibitor UCN-01 (Chen et al, 1999; Busby
et al, 2000), in HeLa cells with doxycycline-inducible expression of
EGFP-tagged E2F7WT and E2F8WT (Tet/ON, hereafter referred to as
HeLa/TO, Fig 1D). We found that inactivation of Chk1 resulted in
a substantial reduction in E2F7S411 and E2F8S395 phosphorylations
compared with control condition. Taken together, these data show
that specific serine residues in E2F7 and E2F8 proteins are bona fide
Chk1 phosphorylation sites.
Chk1-dependent phosphorylation does not alter stabilization or
subcellular relocalization of atypical E2Fs
Given that Chk1 controls the stability of many of its substrates
(Mailand et al, 2000; Raleigh & O’Connell, 2000), we investigated
whether Chk1-dependent phosphorylation alters the stability of
E2F7 and E2F8. We created stable HeLa cell lines with doxycycline-
inducible expression of E2F7S411A and E2F8S395A. In addition to the
alanine mutants, we also generated phosphorylation-mimicking
mutants in which we replaced the respective Ser411 and Ser395 resi-
dues on E2F7 and E2F8 with aspartic acids (hereafter referred to as
E2F7S411D and E2F8S395D). The EGFP tags allowed for separate detec-
tion of exogenous and endogenous E2F7/8 and the over-expression
levels were within the physiologically range and similar between
wild-type and mutant constructs (Fig EV2A). Next, HeLa/TO cells
were treated with doxycycline to induce over-expression and etopo-
side to cause DNA damage and Chk1 activation. Protein levels of
wild-type and mutant E2Fs were not majorly affected by etoposide
treatment (Fig 2A), which implies that neither DNA damage nor
Chk1 kinase has a direct impact on stabilization of E2F7 or E2F8. To
evaluate whether Chk1-dependent phosphorylation may affect
stability of endogenous E2F7 and E2F8, we treated HeLa cells with
etoposide to activate Chk1. Etoposide treatment increased E2F7 and
E2F8 levels within 8 h (Fig 2B). However, since protein expression
of E2F7 and E2F8 oscillates during the cell cycle and peaks during S
phase, we hypothesized that this stabilization could merely reflect
an etoposide-induced accumulation of cells in S phase. Flow cyto-
metry confirmed that etoposide substantially elevated the number of
cells in S phase (Fig 2C). We repeated this experiment in the pres-
ence of the protein synthesis inhibitor cycloheximide. When HeLa
or U2OS cells were treated with etoposide and cycloheximide, the
proportion of cells in S phase and the protein expression of E2F7
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and E2F8 did not change while Chk1 was strongly activated, as seen
by phosphorylation of its Ser345 residue (Figs 2D and EV2B). These
findings provide strong evidence that phosphorylation by Chk1 does
not directly regulate the protein stability of E2F7 and E2F8.
As Chk1 was previously shown to mediate nuclear exclusion of
some of its substrates (Lopez-Girona et al, 1999), we then investi-
gated whether Chk1-dependent phosphorylation could affect the
subcellular localization of E2F7 and E2F8. However, immunoblots
using our phospho-specific antibodies on fractionated protein
lysates showed that both phosphorylated and non-phosphorylated
forms of E2F7 and E2F8 were almost exclusively located within the
nucleus (Fig EV2C). Interestingly, previous work suggested that
E2F7 may bind to DNA damage sites and contribute to the repair of
double-strand breaks (Zalmas et al, 2013). This raised the question
as to whether atypical E2Fs relocalize to DNA lesions in a Chk1-
dependent manner. To visualize the E2F protein dynamics in
response to DNA damage, HeLa/TO cells expressing EGFP-tagged
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Figure 1. Chk1 phosphorylates atypical E2Fs.
A Putative Chk1 substrate motifs in human or mouse E2F7 and E2F8 proteins, and known human Chk1 substrate motifs.
B Schematic overview of the putative Chk1 phosphorylation motifs on mouse E2F7 and E2F8.
C Kinase assay showing that Chk1 phosphorylates mouse E2F7 and E2F8 in vitro. HEK cells were transfected with EGFP-tagged wild-type and mutant versions of E2F7
and E2F8, lysed, and precipitated with GFP-Trap beads. Precipitated proteins were incubated with radiolabeled 32P-ATP, in the presence or absence of recombinant
active Chk1 and loaded onto SDS–PAGE gel.
D Chk1 phosphorylates atypical E2Fs in vivo. 24 h before treatment, siRNA against Chk1 was transfected to HeLa/TO cells. Then, cells were treated either without
doxycycline (Veh) or with doxycycline (Dox) for 16 h to induce the over-expression of wild-type E2F7 and E2F8. UCN-01 was added to the cells simultaneously to
inhibit Chk1 kinase. Whole-cell lysates were harvested for immunoblot.
Source data are available online for this figure.
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Figure 2. Chk1-dependent phosphorylation does not cause stabilization or subcellular relocalization of atypical E2Fs.
A Stability of atypical E2Fs is not affected by Chk1 phosphorylation. HeLa/TO cells were treated with doxycycline to induce over-expression of wild-type or alanine
mutant E2F7 or E2F8, either with or without etoposide to induce DNA damage for 8 h, and protein levels were then measured by immunoblotting.
B Protein expression of endogenous E2F7, E2F8, phos-Chk1S345, and total Chk1 in HeLa cells treated with etoposide at different time points.
C Percentage of cells in S phase was determined by flow cytometry. HeLa cells were treated with etoposide, cycloheximide (CHX), or etoposide (Eto) + CHX, harvested at
the indicated time points, and subjected to flow cytometry and cell cycle analysis. Data are presented as mean  SEM. *P < 0.05 (one-way ANOVA test).
D Protein expression of endogenous E2F7, E2F8, phos-Chk1S345, and total Chk1 in HeLa cells treated with cycloheximide (CHX), in the presence or absence of etoposide
(Eto) at different time points.
E Immunofluorescence staining showing the localization of E2F7, E2F8, and MDC1 in response to micro-irradiation for 1 h in HeLa cells. E2F7, E2F8, and MDC1 were
labeled with GFP, and DNA damage sites are detected with an antibody against c-H2AX. Nuclear DNA was stained with DAPI. Scale bar: 5 lm.
Source data are available online for this figure.
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nucleus, followed by live microscopy imaging. Cells were stained
for c-H2AX to confirm the presence of DNA double-strand breaks.
Surprisingly, we observed no migration of E2F7 or E2F8 to the DNA
damage foci after 1 h of irradiation, while MDC1, a known mediator
of DNA damage repair (Stewart et al, 2003), accumulated rapidly at
DNA lesions (Fig 2E). In order to rule out that the recruitment of
E2F7/8 may be delayed, or dependent on the cell line used, we tried
to repeat the experiment from the previous work by transfecting
U2OS cells transiently with EGFP-E2F7/8 and treated them with
camptothecin for 24 h (Zalmas et al, 2013). Again, while MDC1
localized toward c-H2AX foci, we did not observe recruitment of
E2F7 or E2F8 by utilizing anti-GFP antibody staining (Fig EV2D).
Perhaps the severity of the damage was different from the previous
work, but we did not observe that atypical E2Fs localize to DNA
damage sites.
Chk1 inhibits the transcriptional repressor function of E2F7 and
E2F8 to promote cell cycle progression and prevent apoptosis
The main function of atypical E2Fs is to repress the expression of a
set of genes critical for cell cycle progression. Based on our findings,
we hypothesized that Chk1 phosphorylation affects the repressor
activity of atypical E2Fs. To test this hypothesis, we first evaluated
the impact of mutating the atypical E2F-Chk1 phosphorylation sites
on cell cycle progression. Stable HeLa/TO cell lines containing indu-
cible wild-type and Chk1 mutant versions of atypical E2Fs were
synchronized at the start of S-phase transition by adding the rib-
onucleotide synthase inhibitor hydroxyurea (HU) to the medium for
16 h. Upon release from the HU block, the expression of EGFP-
tagged wild-type and mutant versions of E2F7 and E2F8 was
induced by doxycycline (Dox) and the progression of the respective
cell lines until mitosis was monitored by live cell imaging (Fig 3A).
We observed that approximately 60–70% of E2F7WT- and E2F8WT-
expressing cells completed mitosis within 24 h after HU release,
similar to vehicle-treated non-induced cell lines. However, over-
expression of E2F7WT after HU release resulted in delayed cell cycle
progression compared to vehicle-treated cells, whereas E2F8WT
over-expression had no major impact on the speed of cell cycle
progression. Importantly, cells expressing either the non-phosphory-
latable E2F7S411A or E2F8S395A showed a remarkable delay in cell
cycle progression and only 10% of the cells were able to enter mito-
sis 24 h after HU release. In contrast, cells expressing the phospho-
mimic E2F7S411D and E2F8S395D mutants showed no changes in cell
cycle progression. Flow cytometry analysis suggested that cells
expressing E2F7S411A arrested in both S and G2 phase, while cells
expressing E2F8S395A were mostly halted in G2 (Fig EV3A). To make
sure that these effects are not only specific for hydroxyurea release,
we performed synchronization experiments after a double thymi-
dine block/release assay, which is known to induce less double-
strand DNA breaks in cells compared to HU-treated cells (Lundin
et al, 2002). After 9 h of thymidine release, HeLa/TO cells express-
ing wild-type and phospho-mimetic versions of E2F7 progressed to
an ongoing S phase, while expression of alanine mutant strongly
stalled the cell cycle at the onset of S phase (Fig EV3B). Moreover,
E2F7WT and E2F7S411D cells had mostly completed mitosis after
14 h, while expressing E2F7S411A aggravated the S/G2-phase arrest
phenotype. These data show that cell cycle progression was severely
delayed by non-phosphorylatable forms of E2F7 and E2F8.
Interestingly, during live cell imaging, we observed that a propor-
tion of alanine mutant-expressing cells displayed cell blebbing 24 h
after HU release, which we interpreted as cell death (Fig EV3C).
Flow cytometric analysis of the apoptosis marker Annexin-V
confirmed a higher percentage of apoptosis in E2F7S411A- and
E2F8S395A-expressing compared to wild-type E2F7- and E2F8-
expressing cells (Fig 3B). Given that maintaining E2F target gene
transcription ensured DNA replication and avoid replication stress-
induced DNA damage (Bertoli et al, 2016), a potential explanation
for the apoptosis we observed could be that the alanine mutant
versions of E2F7 and E2F8 strongly repress their target genes, result-
ing in DNA damage and consequently apoptosis.
Next, we determined whether alanine mutant forms of E2F7 and
E2F8 possess higher transcriptional repressor activity compared to
the wild-type versions. Since HU treatment leads to replication
stress and strong activation of Chk1, we treated cells for 16 h with
HU and compared mRNA levels of E2F7/8 target genes after induc-
tion of wild-type or phospho-mutant E2F7 and E2F8. We used fluo-
rescence-activated cell sorting (FACS) to collect cells with similar
EGFP over-expression levels (Fig EV3D, GFP+/GFP) and measured
subsequently RNA levels of E2F target genes by quantitative PCR.
Expression of E2F target genes, such as CDC6 and CCNE1, was
significantly more repressed by non-phosphorylatable alanine
mutants compared to wild types and aspartic mutants (Kent et al,
2016; Westendorp et al, 2012; Fig 3C and D). This finding provides
strong evidence that Chk1 phosphorylation can abrogate the repres-
sor activity of E2F7 and E2F8.
Previous work showed that phosphorylation by Chk1 redirects
E2F6 away from target gene promoters (Bertoli et al, 2013). There-
fore, we tested whether Chk1 phosphorylation has a similar effect
on E2F7 and E2F8. To this end, we transfected HEK 293T cells tran-
siently with wild-type, alanine mutant, or phospho-mimic mutant
E2F7 and E2F8, and used GFP-trap beads to perform chromatin
immunoprecipitation. A primer set designed against a distal region
in the E2F1 gene served as a negative control to show that binding
was specific to E2F binding motif-containing regions (Fig 3E).
However, phospho-mutant and wild-type versions of atypical E2Fs
displayed no clear differences in enrichment on various E2F target
gene promoters (Fig 3E). Thus, Chk1 phosphorylation did not alter
the recruitment ability of atypical E2Fs toward E2F target
promoters.
Taken together, these results indicate that Chk1 inhibits E2F7
and E2F8 function to allow resumption of the cell cycle and prevent
cell death after transient replication stress and DNA damage.
Loss of Chk1 causes E2F7/8-dependent cell cycle arrest and
DNA damage
Chk1 is essential for the stabilization of replication forks, and inhibi-
tion of Chk1 therefore delays DNA replication and failure to
complete S phase (Zachos et al, 2003). Since phosphorylation by
Chk1 inhibits E2F7 and E2F8 repressor function, we hypothesized
that Chk1 inhibition causes S-phase arrest which depends on the
repressor activity of E2F7 and E2F8. To test this, Chk1, E2F7, and
E2F8 alone or in combination were knocked down with siRNAs.
HeLa cells were synchronized by HU treatment for 16 h, and cell
cycle profiles were analyzed at 0, 4 and 8 h after HU release by flow
cytometry. We confirmed efficient knockdown of all three proteins
ª 2018 The Authors The EMBO Journal 37: e97877 | 2018 5 of 17
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with immunoblot analysis (Fig 4A). Moreover, we found that
protein expression of Rad51 and CDC6, which are well-described
E2F target genes, were decreased by Chk1 siRNA, suggesting
enhanced E2F7/8 repressor activity (Fig 4A). Flow cytometry analy-
sis revealed that Chk1 knockdown resulted in a severe S-phase
arrest, whereas knockdown of E2F7/8 had no major impact on cell
cycle progression. Importantly, no S-phase arrest was observed
when Chk1 was knocked down in combination with E2F7/8. This
demonstrates that inactivation of atypical E2Fs can rescue the cell
cycle phenotype induced by Chk1 inhibition (Fig 4B). In addition,
we observed a similar phenotype in RPE-hTERT cells, a non-trans-
formed retina pigment cell line with intact checkpoint functions
(Fig EV4A). We reasoned that if knockdown of Chk1 and E2F7/8
permits the cell cycle progression, then ectopic expression of non-
phosphorylatable E2F7/8 in the same condition would arrest the S-
phase progression again, to a bigger extent than phospho-mimetic
E2F7/8. Indeed, flow cytometry showed that in the presence of
siChk1 + siE2F7+8, cells overexpressing alanine mutant forms of
E2F7 and E2F8 fail to continue S phase after HU release (Fig EV4B).
On the contrary, a substantial amount of aspartic mutant-expressing
cells managed to progress to G2/M phase. These data confirmed our
finding that cell cycle arrest by Chk1 inhibition was dependent on
the deregulated repressor activity of atypical E2Fs.
Our data suggest that Chk1 inactivation results in unrestricted
activity of E2F7 and E2F8, and consequently enhanced repression of
E2F target genes resulting in failure to progress through S phase
after HU release. Indeed, transcription of typical E2F7/8 target genes
such as CDC6, RAD51, CDC25A, and CCNE1 was all significantly
repressed in HU-treated cells with Chk1 knockdown (Fig 4C).
Importantly, additional knockdown of E2F7 and E2F8 relieved this
downregulation of E2F target gene expression and likely explains
why cells can progress properly through the cell cycle. In addition
to the usage of siRNA, we inhibited Chk1 kinase with UCN-01. In
line with Chk1 siRNA experiments, we found that UCN-01 treatment
results in enhanced E2F7/8 target gene repression and impaired
recovery from a HU block, which could be rescued by E2F7 and
E2F8 siRNA treatment (Fig EV4C and D).
Next, we tested whether the transcription control by the
Chk1-E2F7/8 axis affects protein levels of the target genes and its
functional relevance. Rad51 is a target of E2F7 and E2F8, and it relo-
calizes to the DNA lesion sites to promote DNA damage repair
(Shinohara et al, 1992). Consistent with the reduction in overall
Rad51 protein by Chk1 knockdown (Fig 4A), immunofluorescence
staining revealed a marked reduction in nuclear Rad51 intensity
after knockdown of Chk1 in HU-treated cells (Fig 4D, quantification
on the right). Additionally, knockdown of E2F7 and E2F8 in addition
to siChk1 rescued the expression of Rad51 demonstrating that
repression of E2F target gene transcripts had a direct influence on
their protein levels. Given that Rad51 promotes DNA damage repair,
then repression of Rad51 can lead to accumulation of unfixed DNA
lesions. To test this, c-H2AX intensity was measured in the siChk1
condition. Indeed, siChk1 resulted in a dramatic accumulation of
c-H2AX compared to the control condition. Interestingly, the high-
intensity phenotype of c-H2AX was completely resolved in cells
treated with siChk1 + siE2F7+8. These data strongly suggest that
inhibition of E2F7/8 repressor activity by Chk1 is critical for
preventing replication stress-induced DNA damage.
It was documented that Chk1 is essential for the checkpoint func-
tion in an unperturbed cell cycle (Patil et al, 2013). Therefore, we
investigated whether loss of Chk1 affects the progression of the cell
cycle in transformed (HeLa) and non-transformed (RPE) cell lines
under unperturbed conditions. Although Chk1 decreased the
percentage of RPE cells in S/G2, it had little effect on cell cycle
distribution in HeLa cells (Fig EV4E). In both cell lines, the combi-
nation of Chk1 knockdown with knockdown of E2F7/8 showed cell
cycle profiles highly similar to the control condition. In line with the
cell cycle analysis, in a clonogenic cell survival assay we showed
that siChk1 has only a mild effect on long-term HeLa cell survival,
compared to the control condition (Fig EV4F). However, we demon-
strated that loss of Chk1 was detrimental to the long-term cell
survival under HU treatment, which was relieved by combinational
knockdown of E2F7/8. Taken together, these data consistently show
that Chk1 inhibition causes a permanent cell cycle arrest under
conditions of replication stress, which is dependent on E2F7/8
repressor function.
14-3-3 f mediates Chk1-dependent inhibition on E2F7 and E2F8
Given that Chk1 phosphorylation did not inhibit the promoter bind-
ing activity of atypical E2Fs (Figs 3E and EV3D), we evaluated
whether Chk1 phosphorylation interferes with the binding of regula-
tory partners of atypical E2Fs. To test this, we first screened for
putative regulatory E2F7- and E2F8-interacting proteins. To this
end, we performed mass spectrometry using SILAC (Stable Isotope
Labeling with Amino acids in Cell culture). We labeled HeLa/TO
cells expressing EGFP-tagged E2F7 or E2F8 or EGFP only, and
◀ Figure 3. Chk1 inhibits the transcriptional repressor function of E2F7 and E2F8 to promote cell cycle progression and prevent apoptosis.A Left panel shows a schematic view of the experimental setting. HeLa/TO cells were synchronized with hydroxyurea (HU) for 16 h, then released by washing and
adding new medium containing doxycycline (Dox) to induce expression of the transgenes. Cell lines incubated with medium without doxycycline (Vehicle, Veh)
were used as controls. Expression of WT and Chk1 mutant versions of E2F7/8 was monitored by EGFP fluorescence, DNA was visualized by adding fluorescent SiR-
DNA to the medium, and cell morphology was evaluated by differential interference contrast (DIC). Per condition, 100 individual cells were traced. Each cell was
followed until it successfully finished mitosis and divided into two daughter cells, for a maximum of 24 h. The graphs on the right show the quantification of the
mitotic events during live cell imaging. Scale bar: 10 lm.
B Quantification of apoptosis by flow cytometric analysis of Annexin-V staining. Experiments were performed as outlined in (A), and cells were harvested for flow
cytometry 24 h after HU release. Apoptotic cells were counted as Annexin-positive and DAPI-negative.
C, D Quantitative PCR of CDC6, RAD51, CDC25A, and CCNE1 expression in HeLa/TO cell lines expressing wild-type and mutant versions of E2F7/8.
E Chk1 phosphorylation does not change the promoter enrichment of E2F7 and E2F8. HEK cells were transfected with either PEI reagent alone (control) or indicated
plasmids tagged with GFP. 48 h after transfection, cells were harvested for chromatin immunoprecipitation (ChIP) followed by qPCR. Histogram represents the
enrichment ratio (bound/input) in E2Fs target gene promoters.
Data information: In (B–D), data represent average  SEM (n = 3); *P < 0.05 or **P < 0.01 (Student’s t-test in B, and two-way ANOVA in C and D).
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Figure 4. Loss of Chk1 results in E2F7/8-dependent cell cycle arrest and DNA damage.
A Schematic overview of the experimental setting and immunoblot analysis for the validation of the efficient siRNA-mediated knockdown of Chk1, E2F7, and E2F8 at
HU (0 h) or 8 h after HU release. Protein levels of atypical E2Fs targets RAD51 and CDC6 are shown. Detection of c-tubulin was used as loading control.
B FACS cell cycle profiles at 0, 4 and 8 h after HU release from propidium iodide-stained HeLa cells incubated with siRNAs directed against Chk1 and E2F7/8.
Scrambled (scr) siRNA was used as control.
C Transcript levels of E2F7/8 target genes CDC6, RAD51, CDC25A, and CCNE1 after HU treatment for the indicated siRNA groups measured by quantitative PCR. Fold
changes were adjusted to scrambled condition.
D, E Immunofluorescence staining showing the intensities of Rad51 and c-H2AX in HeLa cells. Cells were transfected with indicated siRNA and incubated with HU for
16 h before harvest. Nuclear DNA was stained with DAPI. For quantification (right side), five fields of 40× magnification pictures were selected randomly and
subjected to ImageJ software analysis. Scale bars: 20 lm.
Data information: In (C), data represent average  SEM (n = 3); in (D, E), bars represent average (n = 150); *P < 0.05 or **P < 0.01 (Student’s t-test) or n.s. for not
significant.
Source data are available online for this figure.
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immunoprecipitated nuclear protein extracts with GFP-trap beads.
We then measured the relative abundances of proteins from EGFP-
tagged E2F7 or E2F8 over EGFP only (Fig EV5A). We selected only
proteins with relative enrichment above twofold from both forward
and reverse labeling experiments. With this threshold, we found 86
putative binding partners for both E2F7 and E2F8 (Table EV1). We
noticed that multiple 14-3-3 protein isoforms were among the most
highly enriched common interaction partners (Fig 5A). The 14-3-3
proteins are dimeric proteins, which modulate functions of their
interaction partners primarily via binding in a phosphorylation-
dependent manner (Jones et al, 1995; Muslin et al, 1996). To verify
these interactions, EGFP-tagged E2F7 or E2F8 wild-type or alanine
mutants were co-transfected with Myc-tagged 14-3-3 isotypes f and
e in HEK 293T cells, followed by GFP immunoprecipitation and Myc
immunoblotting. Strikingly, wild-type E2F7 and E2F8 bind to 14-3-3
f and e, and these interactions were completely lost in E2F7S411A
and E2F8S395A mutants (Figs 5B and EV5B). These data show that
the Chk1 phosphorylation site facilitates 14-3-3 binding to E2F7 and
E2F8. Consistently, endogenous phosphorylated E2F7 and E2F8
were immunoprecipitated with Myc-14-3-3 f, implying that E2F7/8
binds to 14-3-3 f in vivo (Fig EV5C). One of the known functions of
14-3-3 protein is to modulate the localization of its binding partner
(Muslin & Xing, 2000). However, phosphorylation mutant E2F7 and
E2F8 remained strictly localized in the nucleus and bind chromatin
to a similar extent (Figs EV2C and EV3C, and 3E). Furthermore, co-
transfection of Myc-tagged 14-3-3 f with GFP-tagged E2F7 and E2F8
on U2OS cells revealed no relocalization of the atypical E2Fs to the
cytosol (Fig EV5D).
Previous work demonstrated that 14-3-3 proteins can be found in
chromatin (Milton et al, 2006). Thus, we reasoned that 14-3-3
proteins can bind to phosphorylated E2F7 and E2F8 at their
promoter regions to modulate their functions. To test our hypothe-
sis, we performed ChIP to investigate whether 14-3-3 proteins are
enriched at the E2F7/8 target promoters. In the ChIP assay, wild-
type E2F7 and E2F8 were set as positive controls, and chromatin
fractions were immune-precipitated by either GFP-trap resin or 14-3-
3 antibody. As expected, E2F7 and E2F8 are specifically enriched at
the promoter regions of their target genes such as E2F1, CHEK1,
RAD51, MCM2, and CDC6 (Figs 5C and EV5E). More importantly,
14-3-3 proteins (f and e) also showed significant enrichment toward
the promoters of the same E2F7/8 target genes. Therefore, our data
indicated that 14-3-3 proteins bind to promoter regions of E2F target
genes likely via interaction with E2F7/8. Next, we investigated
whether binding of 14-3-3 proteins to phosphorylated E2F7 and
E2F8 regulates atypical E2F repressor activity by performing
reporter assays. U2OS cells were co-transfected with EGFP-tagged
E2F7 or E2F8, 14-3-3 f, and an E2F1 promoter-luciferase reporter
plasmid. 14-3-3 f constructs partially inhibited the repressor activity
of wild-type E2F7 and E2F8 on the E2F1 promoter (Fig 5D). In
contrast, co-transfection of 14-3-3 f with alanine mutant E2F7 and
E2F8 could not inhibit the atypical E2F repressor activity, which
suggests that 14-3-3 f binding mediates inhibition of E2F7 and E2F8
repressor function via binding to Chk1 phosphorylation sites. If 14-
3-3 attenuates the repressor function of atypical E2Fs, then disrup-
tion of this interaction should result in an enhanced suppression of
E2F target genes. To test this hypothesis, we used a 14-3-3 docking
inhibitor BV-02 with proven efficacy to disassociate 14-3-3 interac-
tions with its binding partners (Mancini et al, 2011). Indeed, we
found that BV-02 treatment abolished the binding of 14-3-3 f to both
E2F7 and E2F8 (Fig 5E). We then treated cells with HU to activate
Chk1 phosphorylation and evaluated the effect of BV-02 on E2F7/8
target gene expression. Compared to DMSO-treated controls, BV-02
treatment significantly downregulated transcript levels of a panel of
E2F target genes, including CDC6, Rad51, CDC25A, and CCNE1, and
had no impact on E2F7 and E2F8 (Figs 5F and EV5F). To evaluate
whether BV-02 downregulates E2F target genes via E2F7 and E2F8,
we knocked down E2F7 and E2F8 expressions with siRNA technol-
ogy (Fig EV5F). Remarkably, under siE2F7+8 conditions, BV-02
treatment did not result in downregulation of E2F target genes
anymore, indicating that BV-02-mediated repression is dependent
on the presence of atypical E2Fs. Taken together, phosphorylation
by Chk1 creates a docking site for 14-3-3 proteins to directly inhibit
the repressor function of E2F7/8.
We next investigated whether binding of 14-3-3 proteins to
E2F7/8 could alter the dimerization between atypical E2Fs or their
interaction with E2F1. However, co-immunoprecipitation experi-
ments revealed that homodimerization and heterodimerization
between the atypical E2Fs and their binding to E2F1 were not
affected by 14-3-3 proteins (Appendix Fig S1A).To determine
whether 14-3-3 binding has impact on other interaction partners of
the atypical E2Fs, we performed an additional SILAC experiment.
This time, we pulled down E2F7WT or E2F7S411A and investigated
the differential interaction with other proteins. As expected, we
could observe reduced pulldown of 14-3-3 proteins by the alanine
▸Figure 5. 14-3-3 f mediates Chk1-dependent inhibition of E2F7/8.A Scatter plot shows the relative enrichment scores of common E2F7 and E2F8 binding partners. Red dashed line indicates the fold change cutoff (> 2.0). 14-3-3
isoforms are highlighted as red dots.
B 14-3-3 f interacts with wild-type E2F7/8 but not with alanine mutants in vitro. HEK 293T cells were transfected with indicated constructs, and lysates were
precipitated with GFP-Trap beads and immunoblotted with antibodies directed against Myc or GFP. Inputs represent loading controls.
C Chromatin immunoprecipitation (ChIP) demonstrated that 14-3-3 proteins bind to the E2F7/8 target gene promoters. HEK cells were transfected with either PEI
reagent alone (control) or indicated plasmids. 48 h after transfection, cells were harvested for ChIP assay and followed by qPCR. Histogram represents the enrichment
ratio (bound/input) in E2Fs target gene promoters. A primer set designed against a distal region in the E2F1 gene served as a negative control.
D Luciferase reporter assay in U2OS cells using E2F1 promoter plasmid. Plasmids were co-transfected either with wild-type or alanine mutant, either alone or with
14-3-3 f plasmid.
E 14-3-3 inhibitor BV-02 disrupts the interaction between 14-3-3 f and E2F7/8. Transfection was carried out as shown, and lysates were precipitated with GFP-Trap
beads and immunoblotted with antibodies directed against GFP or Myc. Inputs represent loading controls.
F Transcript levels of common E2F7 and E2F8 target genes after treatment with HU or HU + BV-02 for 16 h, determined by qPCR.
Data information: In (C, D and F), data represent average  SEM (n = 3); *P < 0.05 (Student’s t-test) or n.s. (not significant).
Source data are available online for this figure.
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mutant, confirming the validity of the assay (Appendix Table S1).
However, only very few other proteins were differentially enriched,
and the majority of those are suspicious contaminating proteins in
mass spectrometry experiments and none of these differentially
expressed proteins are known for the capability to function as co-
repressors. Taken together, this finding suggests 14-3-3 recruitment
to E2F7/8 target promoters does not alter the dimerization or the
interaction of co-repressors of atypical E2Fs. 14-3-3 binding might
be still able to physically hinder the intrinsic repressor function of
DNA-bound E2F7/8, which would require the design of complex
studies to test the conformational status of atypical E2Fs.
Gene amplification of the 14-3-3 f is associated with
upregulation of E2F7/8 target genes in human cancer
We noticed that the gene YWHAZ, which encodes for 14-3-3 f, is
frequently amplified in various types of cancer and associated
with oncogenic activity (Lin et al, 2009; Li et al, 2010; Chen et al,
2012). Additionally, E2F target genes are over-expressed in many
types of cancer, including hepatocellular carcinoma, despite high
expression of the E2F7 and E2F8 repressors (Kent et al, 2016).
Since 14-3-3 has the ability to inhibit the transcriptional repressor
function of the atypical E2Fs, we wondered whether 14-3-3
expression correlates with increased expression of E2F7/8 target
genes in human cancer. To this end, we first analyzed the expres-
sion data provided by the R2 platform of the AMC oncogenomics
project [R2: Genomics Analysis and Visualization Platform
(http://r2.amc.nl)]. Four types of cancer, breast invasive carci-
noma, prostate cancer, pancreas cancer, and liver hepatocellular
carcinoma, were enrolled, based on the high frequency of
YWHAZ amplifications in these types of cancer (15–30%). R
value (> 0.3) and P-value (< 0.01) were set to identify which
upregulated E2F target transcripts correlate with upregulated 14-3-
3 f transcripts. For this query, 79 known E2F7/8 target genes
(Westendorp et al, 2012; Kent et al, 2016) were selected and are
listed in Table EV2. We found a strong positive correlation
between a large set of highly expressed E2F7/8 target transcripts
and high transcript levels of 14-3-3 f (Fig 6A). It is noteworthy
that genes encoding 14-3-3 proteins are not E2F target genes by
themselves, neither do they oscillate throughout the cell cycle
(Dougherty & Morrison, 2004). This rules out that the co-expres-
sion of 14-3-3 f transcripts and E2F target genes could simply be
explained by variation in the numbers of proliferating cells
between tumor samples. In a second approach, we analyzed
RNA-sequencing data of primary hepatocellular carcinoma in The
Cancer Genome Atlas (TCGA). We compared the expression of
the 79 known E2F7/8 target genes in the 10% highest and lowest
14-3-3 f-expressing tumor samples. Supporting our notion, highest
14-3-3 f RNA levels associated with amplified or copy number
gains of the YWHAZ gene, supporting a gene dosage effect
(Fig 6B). More importantly, the heatmap analysis demonstrated
that E2F7/8 target genes were upregulated predominately in the
samples with the highest 14-3-3 f expression. Similarly, high
levels of 14-3-3 e mRNA, the other E2F7/8 binding partner, corre-
lated strongly with high E2F7/8 target genes (Fig 6C), indicating
that 14-3-3 e also negatively regulates transcription function of
E2F7 and E2F8. These results indicate that upregulation of 14-3-3
proteins, for example, via YWHAZ copy number gains, may inac-
tivate the atypical E2F repressor function, thereby permitting high
levels of E2F-dependent transcription in cancer.
Discussion
The repressor activity of atypical E2Fs needs to be tightly regulated
to avoid severe disturbances of cell cycle progression. Here, we
show a novel mechanism for how the repressor activity of atypical
E2Fs can be inhibited through direct phosphorylation by Chk1
which provides a docking station for 14-3-3 proteins to interact with
E2F7 and E2F8 (Fig 6D). Previous studies have demonstrated that
increased repressor activity of atypical E2Fs downregulates the
expression of a large number of cell cycle genes resulting in a severe
cell cycle arrest accompanied by increased DNA damage and apop-
totic events (de Bruin et al, 2003; Maiti et al, 2005; Westendorp
et al, 2012; Boekhout et al, 2016). Our findings provide strong
evidence for a regulatory mechanism that suppresses the atypical
E2F activity in order to avoid detrimental effects on cell cycle
progression and cell survival under DNA-damaging conditions.
In response to DNA damage, Chk1 is activated and whereby it
inhibits the Cdc7/Dbf4 complex and facilitates the degradation of
CDC25A resulting in S-phase arrest. This sequence of molecular
events transiently prevents the firing of new replication origins,
contributing to the maintenance of genomic integrity (Zhao et al,
2002; Heffernan et al, 2007). Nonetheless, it is also essential to keep
the DNA replication machinery ready to resume once the lesions are
resolved, as long-term replication fork stalling is catastrophic to cell
survival (Dimitrova & Gilbert, 2000; Lopes et al, 2001). Recent work
showed that the persistent transcription of E2F target genes during
DNA repair which means that replication can readily be resumed is
key to prevent further replication stress-induced DNA damage
(Bertoli et al, 2016). Chk1 plays an important role in the mainte-
nance of E2F-dependent transcription since it reduces the binding of
▸Figure 6. High 14-3-3 f and e expression levels are associated with high E2F7/8 target gene expression in human cancer.A Pie charts showing the percentage of upregulated E2F7/8 target genes that correlate with elevated 14-3-3 f expression in four types of cancer. In total, 79 known
target genes were enrolled as E2F7/8 targets. In the R2 database, co-expressed elevated 14-3-3 f and E2F7/8 target transcripts were selected based on regression
analysis, then R (regression value) > 0.3 and P < 0.01 were set to distinguish the significant positive correlation.
B Heatmap showing a positive correlation between 14-3-3 f expressions with E2F7/8 target gene expression. Columns represent 82 hepatocellular carcinoma samples
classified into either the 10% highest or lowest 14-3-3 f mRNA levels. Rows represent 79 E2F7/8 target genes. Amplification: multicopy gain; gain: single copy
amplification; diploid: diploid chromosomes; loss: homozygous or heterozygous loss.
C Heatmap showing a positive correlation between 14-3-3 e expressions with E2F7/8 target gene expression levels derived from the TCGA liver cancer RNA-seq data.
Column represents hepatocellular carcinoma samples classified into groups with either the 10% highest or lowest 14-3-3 e transcript levels. Rows represent 79 E2F7/8
target genes.
D Summary model for the interaction of Chk1 and 14-3-3 with E2F7/8 and other Chk1-E2Fs interplays under DNA damage and replication stress condition.
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the E2F6 repressor to its promoter, while the functions of the acti-
vating E2Fs (E2F1, E2F3) are stimulated by DNA damage signaling
(Stevens et al, 2003; Martinez et al, 2010; Bertoli et al, 2013). Here,
we identify a novel pathway by which E2F target transcription is
regulated by showing that Chk1 phosphorylates and attenuates
the repressor activity of E2F7 and E2F8 under DNA-damaging
conditions.
Our findings show that unlike for other E2F family members,
Chk1 phosphorylation has no impact on either the stability or DNA-
binding ability of E2F7 and E2F8. Instead, Chk1 phosphorylation
creates a binding site for 14-3-3 proteins. The 14-3-3 family has
overwhelming functional diversity in the regulation of cellular
processes including signal transduction, cell cycle progression, tran-
scription regulation, and DNA damage signaling (Dougherty &
Morrison, 2004). Previous studies showed that 14-3-3 stimulated
E2F transcription through stabilizing E2F1 and binding to DP-3
(Dimerization Partner 3) (Wang et al, 2004; Milton et al, 2006).
Based on our data, we excluded the possibility that 14-3-3 proteins
relocate or de-stabilize atypical E2Fs. Since our ChIP assay demon-
strated the enrichment of 14-3-3 at the E2F7/8 target gene promot-
ers, 14-3-3 regulates the transcriptional repressor activity of the
atypical E2Fs most likely in the chromatin. Previous studies have
shown that 14-3-3 dimer binding can result in an extended confor-
mation change of its target peptide and that 14-3-3 dimer can bind
with very high affinity to target peptide containing two phosphoser-
ine motifs (Yaffe et al, 1997). Although 14-3-3 does not alter the
binding affinity between atypical E2Fs, it is possible that 14-3-3 can
structurally alter the conformation of the E2F7/8 dimers by position-
ing itself in between the two individual molecules and thereby
inhibit the transcriptional repressor function of the atypical E2Fs.
We also evaluated whether ATR, one of the upstream regulator
of Chk1, is required for controlling cell cycle progression via E2F7/
8, but inactivation of ATR had no obvious impact on cell cycle
progression under HU conditions (Appendix Fig S1B). It should be
noted that although Chk1 activation inhibited the repressor activity
of E2F7 and E2F8, this is presumably not a complete inactivation.
Firstly, the phospho-mimetic versions of E2F7 and E2F8 (D-
mutants) could still partially repress E2F target gene expression.
Secondly, we previously found that deletion of E2F7/8 abrogated
the cell cycle arrest in keratinocytes treated with the topoisomerase
inhibitor etoposide (Thurlings et al, 2016). Etoposide treatment
causes activation of Chk1, suggesting that residual activity of E2F7/
8 mediates a cell cycle arrest under these conditions. Importantly,
we show here that cells expressing non-phosphorylatable forms of
E2F7/8 underwent severe apoptosis. Based on these observations,
we propose that carefully balanced activity of the atypical E2Fs is
critical to induce S-phase arrest, while preventing detrimental effects
on cell survival during DNA replication stress.
The novel Chk1/14-3-3/E2F7/8 axis that we demonstrate in the
present work has substantial relevance to cancer biology. Atypical
E2Fs can inhibit cell proliferation by repressing a large network of
genes that are essential for S-phase progression. In line with this
function, we recently demonstrated in two different mice condi-
tional knockout models that atypical E2Fs act as tumor suppressors
(Kent et al, 2016; Thurlings et al, 2016). Paradoxically, E2F7 and
E2F8 transcripts are highly expressed in multiple types of human
cancer, and their high expression levels often correlated with poor
prognosis (Endo-Munoz et al, 2009; Deng et al, 2010; Park et al,
2015). It is possible that the elevated expression of E2F7 and E2F8
reflects a high proliferative status of cancer cells (Kent et al, 2016).
Moreover, since atypical E2Fs can be transcriptionally upregulated
by other E2Fs activators (de Bruin et al, 2003; Maiti et al, 2005),
high E2F7/8 expression could result from high levels of E2F activa-
tor-dependent transcription within a tumor sample. Crucially, our
current data show that expression levels of atypical E2Fs do not
necessarily represent their activity, since Chk1-dependent binding of
14-3-3 proteins can attenuate their repressor function. Moreover,
Chk1 protein is frequently induced in many cancers (Verlinden
et al, 2007; Xu et al, 2013), and corresponding Chk1 phosphoryla-
tion of E2F7 and E2F8 was identified in proteomic screens of cancer
tissues and cell lines (Zhou et al, 2013; Mertins et al, 2016). Thus,
E2F7 and E2F8 could be functionally inhibited in cancer cells via
Chk1 and 14-3-3, despite their high transcript levels.
Noteworthy is the finding that the 14-3-3 f isoform which modu-
lates cell cycle and metabolism (Lim et al, 2015; Schoenwaelder
et al, 2016) is also frequently amplified and upregulated in different
types of cancer. It was found to potentiate the oncogenic capacity of
cancer cells via reducing apoptosis, enhancing proliferation, and
increasing chemotherapy resistance, via incompletely understood
mechanisms (Matta et al, 2012). In the exploration of the TCGA
transcriptome database, we identified a positive correlation between
high 14-3-3 f expression and increased expression of many E2F7/8
target genes. This is consistent with our observation that 14-3-3 f
inhibits E2F7/8 function. Our data suggest that 14-3-3 could
compromise the transcriptional repressor function of E2F7 and E2F8
in cancer cells by maintaining high levels of E2F target gene
expression and thereby potentially promoting uncontrolled cell
proliferation.
Materials and Methods
Cell culture, cell line generation, and transfection
HeLa, U2OS, hTERT-RPE1, and HEK 293T cell lines were obtained
from the ATCC and cultured in DMEM (41966052, Thermo Fisher
Scientific) containing 10% fetal bovine serum (10500064, Life Tech-
nologies). Site-directed mutagenesis was performed by two-step PCR
amplification (PCR protocol and primers are provided in Table EV3),
and mutation was confirmed with Sanger sequencing (Macrogen,
Inc). Tet repressor-expressing HeLa-inducible cell lines (HeLa/TO)
were generated as previously described (Westendorp et al, 2012).
The inducible cells lines were cultured in DMEM containing 10%
Tet-approved fetal bovine serum (CL 631106, Clontech), and over-
expression was induced by adding 0.2 lg/ml doxycycline (D9891,
Sigma-Aldrich). Other drugs used in this study were as follows:
etoposide (10 lM, E1383, Sigma-Aldrich); hydroxyurea (2 mM,
H8627, Sigma-Aldrich); thymidine (2 mM, T9250, Sigma-Aldrich);
camptothecin (20 lM, C9911, Sigma-Aldrich), cycloheximide
(50 lg/ml, 01810, Sigma-Aldrich); UCN-01(0.3 lM, U6508, Sigma-
Aldrich); and BV-02 (5 nM, SML0140, Sigma-Aldrich).
Transfection of HEK cells was performed by mixing 130 lg/ml
PEI (polyethylenimine, 23966, Polysciences) with desired plasmids
(15 lg) at a ratio of 1:1 in DMEM. Mixtures were added to the cells
for 6 h and then replaced with fresh medium. U2OS cells were
transfected with Lipofectamine 2000 (11668019, Thermo Fisher
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Scientific) according to the protocol. ON-Target plus SMARTpool
siRNAs (2 nM) were products from GE Dharmacon; transfection
was performed according to the manufacturer’s protocol utilizing
RNAiMax (13778075, Thermo Fisher Scientific). The following
siRNA products were used: Dharmacon L-003255-00-0005
(siCHEK1), Thermo Fisher HSS175354 (siE2F7), Thermo Fisher
HSS128758/HSS128760 (siE2F8), Dharmacon D-001210-02-05
(Scrambled).
Mass spectrometry
For SILAC experiments, HeLa/TO-inducible cells lines were cultured
with Heavy/Light Medium for 2 weeks to incorporate isotopically
labeled lysine (K8, 282986440, Silantes) and arginine (R10,
282986404 Silantes). Sixteen hours after the induction of over-
expression with doxycycline, cells were lysed in RIPA buffer with
50 mM Tris–HCl, 1 mM EDTA, 150 mM NaCl, 0.25% deoxycholic
acid, 1% Nonidet-P40, 1 mM NaF and NaV3O4, and protease inhi-
bitor cocktail (11873580001, Sigma-Aldrich), and desired proteins
were immunoprecipitated. When applicable, heavy and light
samples were mixed. Precipitated proteins were denatured with 8 M
urea in 1 M ammonium bicarbonate (ABC) reduced with 10 mM
TCEP at RT for 30 min after which the cysteines were alkylated with
chloroacetamide (40 mM end concentration) for 30 min. After four-
fold dilution with ABC, proteins were on-bead digested overnight at
RT with 150 ng of Trypsin/LysC (V5071, Promega). After sample
cleanup with in-house-made stage tips, peptides were separated on
a 30-cm pico-tip column (50 lm ID, New Objective) and were in-
house packed with 3 lm aquapur gold C-18 material (Dr. Maisch)
using a 140-min gradient (7–80% ACN 0.1% FA), delivered by an
easy-nLC 1000 (LC120, Thermo Scientific), and electro-sprayed
directly into an Orbitrap Fusion Tribrid Mass Spectrometer
(IQLAAEGAAPFADBMBCX, Thermo Scientific). Raw files were
analyzed with the MaxQuant software version 1.5.1.0. with oxida-
tion of methionine and STY phosphorylation set as variable modifi-
cations, and carbamidomethylation of cysteine set as fixed
modification. The Human protein database of UniProt, with the
mouse E2F8 sequence added, was searched with both the peptide as
well as the protein false discovery rate set to 1%.
Immunoblot and immunoprecipitation
Cells were washed twice with PBS and scraped from the culture
dish. RIPA buffer consisting of 50 mM Tris–HCl, 1 mM EDTA,
150 mM NaCl, 0.25% deoxycholic acid, 1% Nonidet-P40, 1 mM
NaF and NaV3O4, and protease inhibitor cocktail (11873580001,
Sigma-Aldrich) was added to lyse the cells. After 12,000 g
centrifugation for 10 min, supernatants were collected and
proceed to a standard SDS–PAGE Immunoblot. The phospho-
specific antibodies against E2F7S411 and E2F8S395 were customized
products from Davids Biotechnologie GmbH, Germany. All anti-
bodies used in this paper are listed in Table EV3. For immunopre-
cipitations, cell lysates were obtained with RIPA buffer and
immunoprecipitation was carried out by incubating with 4 lg of
the desired antibody per IP (Table EV3) and Protein G Plus/
Protein A Agarose Suspension (IP05-1.5, Calbiochem). For Flag-IP
and GFP-IP in this study, 20 ll of anti-FLAG M2 Affinity Gel
(A2220, Sigma-Aldrich) and GFP-Trap (gta-20, ChromoTek) were
used, respectively. After the pulldown, the agarose beads were
washed three times with RIPA and PBS before proceeding to a
standard SDS–PAGE immunoblot.
Kinase assay
The desired proteins were isolated with immunoprecipitation as
described above. Proteins were washed with TE buffer (20 mM Tris
pH 7.5, and 2 mM EDTA). Incubation was carried out in a reaction
buffer with TE buffer plus 20 mM MgCl2, 1 mM DTT, 200 lM ATP,
in addition to 1 ll ATP32 and 1 ll recombinant active Chk1 (1630-
KS-010, R&D Systems) per reaction. Samples were incubated 30 min
at 30°C with gentle shaking. Laemmli buffer was added to stop the
reaction. Then samples were boiled and loaded on an SDS–PAGE
gel. Radioactive signal was visualized by exposure to a film
(28906836, GE Healthcare).
Flow cytometry and sorting
For the cell cycle analysis, cells were trypsinized, fixed with 70%
ethanol, and stored at 4°C. Cells were washed twice with TBS and
then resuspended with propidium iodide (PI, P4170, Sigma-Aldrich)
staining buffer containing 20 lg/ml PI, 250 lg/ml RNase A, and
0.1% bovine serum albumin. Samples were analyzed on a BD FACS-
Canto II flow cytometer. For Annexin-V staining, cells were trypsi-
nized and staining was performed according to manufacturer’s
instructions (A35110, Life Technologies). The BD Influx system was
used to sort GFP-expressing cells (Dox) and GFP-negative cells
(Veh). Cells were collected and washed twice with PBS before sort-
ing. For each RNA isolation, 25,000 cells were harvested.
Immunofluorescence, stripe assay, and live imaging
Cells were seeded over coverslips (5 mm) and treated with desired
condition as indicated. Cells were first treated with ice-cold 0.2%
Triton X-100 for 1 min, then fixed with 4% PFA at room temperature
for 20 min, followed by 0.1% Triton X-100 at room temperature
20 min. 4% BSA or 10% goat serum were used as blocking reagents,
and samples were then treated with primary and secondary antibod-
ies, respectively, at room temperature for 2 h. Nuclei were stained
with DAPI (F6057, Sigma-Aldrich), and coverslips were mounted
using FluoroshieldTM. Antibodies used in IF are listed in Table EV3.
For live cell imaging, 8,000 HeLa/TO cells were subcultured into
a glass-bottom l-Slide 8-well plate and treated with the desired
conditions. Before live imaging, SiR-DNA (1 lM, SC007, Spiro-
chrome) was added to visualize DNA. For the stripe assay, micro-
irradiation of the nucleus was performed with a 405-nm laser diode
and 4 mW and 50% power, and analyzed with the Nikon A1R
microscope system. Nuclear fluorescence enrichment was observed
for up to 1 h. Afterward, immunofluorescence staining was
performed on the cells that had undergone micro-irradiation. Photo-
graphs were acquired from EGFP (488 nm), far-red (652 nm), and
DIC channels every 30 min.
Quantitative PCR
Isolation of RNA, cDNA synthesis, and quantitative PCR were
performed as previously described (Westendorp et al, 2012). Gene
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transcript levels were determined using DDCt method for multiple-
reference gene correction. b-Actin and GAPDH were used as refer-
ences. Primer sequences are provided in Table EV3.
Reporter assay
U2OS cells (50,000 per triplicate) were seeded to three triplicate
wells in a 24-well plate for each transfection. Each transfection mix
(10 ll per well) contains 500 ng E2F1 luciferase reporter, 20 ng TK
(thymidine kinase) renilla, 100 ng expression or control plasmid,
and 5 ll Superfect Reagent (301305, Qiagen). After 48 h of transfec-
tion, reporter signal was measured using the Dual-Luciferase
Reporter Assay System (E1910, Promega) on a microplate luminome-
ter (Centro LB960). TK was used for normalization of the result.
Clonogenic survival assay
HeLa cells (300,000 per duplicate) were seeded into a six-well plate.
siRNA transfection was conducted after 24 h of cell seeding.
Twenty-four hours after siRNA transfection, cells were trypsinized
and reseeded to a new six-well plate (20,000 per well). Cells were
treated with or without HU for 72 h. Then, medium was removed
with PBS, and cells were fixed with acetic acid/methanol 1:7 (vol/
vol) for 5 min. Colonies were stained with 0.5% crystal violet for
2 h and then rinsed in tap water. Pictures were taken and loaded to
Photoshop CS6 for quantification. For each condition, 10 fields
(300 × 300 pixels) were randomly selected. Positive colony staining
was measured with Magic Wand Tool, with tolerance value set to
32. Relative intensity was defined as the ratio of positive purple-
staining area (in pixels) over total area (300 × 300 pixels). Histo-
grams in Fig EV4F show the quantification from two independent
experiments.
R2 database and TCGA data analysis
In the R2 platform, four expression datasets were selected for the
pie chart (Fig 6A): Tumor Breast Invasive Carcinoma-TCGA-1097-
rsem-tcgars; Tumor Prostate Adenocarcinoma-TCGA-497-rsem-
tcgars; Tumor Pancreatic adenocarcinoma-TCGA-178-rsem-tcgars;
Tumor Liver Hepatocellular Carcinoma-TCGA-371-rsem-tcgars.
Type of analysis: Find Correlated genes with a single gene and gene
name: YWHAZ. Genes were filtered with R value (> 0.3) and P-
value (< 0.01). Analysis of TCGA data was performed as follows:
All available RNA-sequencing and copy number variation data from
the liver cancer dataset (LIHC) were downloaded as level 3 data.
Subsequent analysis was performed in Rstudio version 3.3.0 using
the packages “rjson”, “parallel”, “GenomicRanges”, and “Hmisc” in
combination with a number of custom R scripts and functions to
merge all data, remove non-tumor samples, and call segment mean
values for the YWHAZ gene locus in each sample. FPKM values
(Fragments Per Kilobase Million) were used to calculate log-fold
changes, and heatmaps were generated using the R package
Pheatmap. All used codes are available on request.
Statistical analysis
Immunoblots (except kinase assay), immunoprecipitation, reporter
assay, flow cytometry, FACS, and qPCR results were repeated
three times unless otherwise stated in the figure legends. Percent-
ages of cells in S phase were calculated using the cell cycle anal-
ysis function in FlowJo v10.0 software. Statistical analyses on
FACS qPCR in Fig 3 was done using ANOVA followed by
Dunnett’s post hoc comparisons. Statistical analyses on Annexin-
V, qPCR and reporter assay, staining in Figs 3–5 were analyzed
with the t-test.
Expanded View for this article is available online.
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